ISSN: 2577-4301
Authors: Ayman Esmail Hussien and Osama Allam Mandour
Background: A study was conducted to investigate the use of levofloxacin, azithromycin, and oseltamivir in the treatment of COVID-19 Omicron. The results showed that this combination therapy reduced hospital stays, improved survival rates, cleared lung pathological changes faster, and reduced the need for invasive mechanical ventilation. Omicron is a highly infectious variant of the coronavirus that has caused a global surge in cases. The WHO is currently assessing the effectiveness of various medications against Omicron, including monoclonal antibody therapy and antiviral drugs. The choice of oseltamivir in this study was based on its success in managing COVID-19. Levofloxacin and azithromycin were included in the treatment protocol due to their effectiveness in treating pneumonia caused by COVID-19. Many hospitals have adopted this treatment protocol. Results: Analysis of forty patients included time spent in the hospital, survival rate, enhanced clearance of lung pathological changes, and requirements for invasive mechanical ventilation. Conclusions: combination therapy significantly improved patient outcomes, evidenced by shorter hospital stays (average of 6.05 days for the treated group vs. 33.68 days for the control group), faster clearance of lung pathology within 1 to 2 months, and increased survival rates. The treatment also reduced the need for invasive mechanical ventilation.
Keywords: Covid 19 Omicron; Levofloxacin; Azithromycin; Oseltamivir
